Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PANTOPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PANTOPRAZOLE SODIUM.
ACIPHEX SPRINKLE vs PANTOPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
20 mg orally once daily as delayed-release capsules; maximum dose 40 mg per day.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in healthy subjects; prolonged in CYP2C19 poor metabolizers (up to 3-4 hours). Clinically, the short half-life results in rapid clearance but sustained acid suppression due to irreversible binding to the proton pump.
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Primarily hepatic metabolism (CYP2C19 and CYP3A4); <1% excreted unchanged in urine; approximately 90% of the dose excreted as metabolites in urine and feces via biliary elimination.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor